UPDRS Motor Score (MDS-UPDRS Part III)
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III motor examination. Assesses motor features of Parkinson disease. Scores 0 (normal) to 132 (severe). Used to titrate dopaminergic therapy.
Score interpretation
→ UPDRS Motor Mild (0–5): Minimal motor impairment. Optimise dopaminergic therapy; exercise (aerobic + balance training); physiotherapy; occupational therapy for ADL strategies; speech and language therapy if dysarthric.
→ UPDRS Motor Moderate (6–14): Moderate motor impairment. Review and optimise levodopa/dopamine agonist dosing; consider DBS evaluation if motor fluctuations or dyskinesias; refer to MDT Parkinson clinic; falls risk assessment.
→ UPDRS Motor Severe (≥15): Severe motor impairment. Advanced therapy review: apomorphine pump, levodopa-carbidopa intestinal gel, or DBS if appropriate candidate; palliative and rehabilitation input; carer support; care home assessment.
Interpretation bands for the UPDRS Motor. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Entacapone · COMT Inhibitor — Parkinson's Disease
- Ropinirole · Dopamine Agonist — Parkinson's Disease
- Rasagiline · MAO-B Inhibitor — Parkinson's Disease
- Riluzole · Neuroprotective Agent — ALS/Motor Neurone Disease
- Dimethyl Fumarate · Disease-Modifying Therapy — Relapsing-Remitting Multiple Sclerosis
- Natalizumab · Disease-Modifying Therapy — MS (Anti-VLA-4 Monoclonal Antibody)
- Acute Stroke / TIA Assessment · NICE NG128; RCP Stroke Guidelines 2023
- Status Epilepticus (Adults) · NICE CG137; ESEM guidelines; RCP Neurology Guidelines
- Suspected Subarachnoid Haemorrhage · NICE NG228; RCEM 2023; AHA/ASA 2023
- Adult Head Injury · NICE NG232 (2023)
- Bell's Palsy / Facial Nerve Palsy · ENT UK 2017; AAN
- Vertigo Workup · ENT UK; NICE CKS
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.